Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LPL | P06858 | 3/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211744 | 0.99 | KDM4E (0.52) | KDM4ESMN1; SMN2ROCK1ALDH1A1LPL | |
| SCHEMBL428922 | 0.88 | CYP2A13 (0.50) | KDM4ESMN1; SMN2ROCK1ALDH1A1LPL | |
| SCHEMBL18579955 | 0.88 | ROCK1 (0.53) | KDM4ESMN1; SMN2ROCK1ALDH1A1LPL | |
| SCHEMBL34461817 | 0.88 | ALDH1A1 (0.44) | KDM4ESMN1; SMN2ROCK1ALDH1A1LPL | |
| SCHEMBL3264764 | 0.87 | ROCK1 (0.52) | KDM4ESMN1; SMN2ROCK1ALDH1A1LPL | |
| SCHEMBL20198185 | 0.87 | ROCK1 (0.49) | KDM4ESMN1; SMN2ROCK1ALDH1A1LPL | |
| SCHEMBL3264221 | 0.87 | ROCK1 (0.49) | KDM4ESMN1; SMN2ROCK1LPLLIPG | |
| SCHEMBL18580183 | 0.87 | ROCK1 (0.45) | KDM4ESMN1; SMN2ROCK1ALDH1A1CXCR3 | |
| SCHEMBL2798956 | 0.85 | ROCK1 (0.50) | KDM4ESMN1; SMN2ROCK1ALDH1A1LPL | |
| SCHEMBL20680449 | 0.85 | ROCK1 (0.47) | KDM4ESMN1; SMN2ROCK1ALDH1A1LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-02-13 | — | — | US | disclosed |
| US-12054483-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-08-06 | — | — | US | disclosed |
| US-20220041590-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-02-10 | — | — | US | disclosed |
| EP-3856186-A1 | SMALL MOLECULE INHIBITORS OF DYRK1/CLK AND USES THEREOF | Arizona Board of Regents on behalf of the University of Arizona (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164476-A | Small molecule inhibitor of DYRK1/CLK and application thereof | 代表亚利桑那大学的亚利桑那校董会 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020069418-A1 | SMALL MOLECULE INHIBITORS OF DYRK1/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | KDM4E 2135/4885SMN1; SMN2 3372/4885ROCK1 1035/4885 |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | KDM4E 2963/4885SMN1; SMN2 4476/4885ROCK1 1686/4885 |
| US-20220041590-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | KDM4E 2963/4885SMN1; SMN2 4476/4885ROCK1 1686/4885 |
| US-12054483-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK2, CLK1, CLK3 | KDM4E 2963/4885SMN1; SMN2 4476/4885ROCK1 1686/4885 |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | KDM4E 2963/4885SMN1; SMN2 4476/4885ROCK1 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.